Adalimumab News and Research

RSS

Adalimumab is an injectable prescription drug used to treat diseases of the immune system; it is marketed by Abbot as Humira. It is one of three drugs that work by inhibiting the potent inflammatory molecule tumor necrosis factor-alpha (TNF-alpha); the others are etanercept (Enbrel) and infliximab (Remicade). Like etanercept and infliximab, adalimumab is a large protein molecule made with recombinant DNA technology. Adalimumab is a monoclonal antibody of the IgG1 subtype that has been "humanized", meaning that all of its components are derived from human molecules.

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Researchers compared changes in inflammatory bowel disease treatment strategies before and after the introduction of biologics in Japan.

24 Aug 2023

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

Researchers examined the association between antidrug antibodies and the response to treatments for rheumatoid arthritis.

17 Jul 2023

"Smart" sutures can detect inflammation and release drugs

Inspired by sutures developed thousands of years ago, MIT engineers have designed "smart" sutures that can not only hold tissue in place, but also detect inflammation and release drugs.

16 May 2023

Clinical trial findings may be a game changer in the treatment of pediatric Crohn's disease

Crohn's disease is a lifelong inflammatory bowel disease (IBD) that is characterized by swelling in the lining of the digestive tract, causing severe diarrhea, abdominal pain, and rectal bleeding.

3 Apr 2023

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Researchers investigated whether mRNA technology-based COVID-19 vaccines promote the development of autoantibodies.

14 Mar 2023

Study shows how arthritis affects people's working lives

The typical person living with arthritis in the UK is 20% less likely to be in work than their equivalent without the condition, new research shows.

30 Jan 2023

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

The American Society of Colon and Rectal Surgeons has issued updated guidelines for physicians, published in Diseases of the Colon & Rectum, about how to treat problems of the anus and rectum called anorectal abscess, anal fistula, and rectovaginal fistula.

22 Jul 2022

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

Researchers assessed the risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immunomodulatory therapies.

13 Jun 2022

People with inflammatory immune conditions had increased risk of COVID-19-related death before vaccination

People with certain inflammatory immune conditions affecting the joints, bowel and skin, such as rheumatoid arthritis, may have been more at risk of dying or needing hospital care if they got COVID-19 before vaccination compared with the general population, according to a new study published in The Lancet Rheumatology.

9 Jun 2022

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Researchers at the Kennedy Institute, University of Oxford, led by Professor Jagdeep Nanchahal have demonstrated the efficacy of the anti-TNF drug adalimumab for patients with early-stage Dupuytren's disease.

30 Apr 2022

Research provides a roadmap for new therapies to treat chorioamnionitis

One of the serious complications that can occur during late pregnancy happens when the amniotic sac (also called the bag of waters) breaks too early, which can allow bacterial infections to cause dangerous tissue inflammation around the placenta.

30 Mar 2022

Intensive treatment for patients with Crohn's disease found to be safe

Intensive treatment for patients with Crohn's disease showed no safety differences compared to the current standard of care, according to a trial published in the journal Gastroenterology.

1 Mar 2022

Biosimilars could drive down drug prices and lead to $38.4 billion savings

Biosimilar drugs could drive down prices for expensive medicines used to treat illnesses such as cancer and rheumatoid arthritis, with savings estimated to be $38.4 billion or 5.9% of projected total U.S. spending on biologics from 2021 to 2025, according to a new RAND Corporation study.

10 Jan 2022

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Adalimumab News and Research

How have inflammatory bowel disease treatments changed after the introduction of biologics?

Are antidrug antibodies reducing the effectiveness of rheumatoid arthritis treatment?

"Smart" sutures can detect inflammation and release drugs

Clinical trial findings may be a game changer in the treatment of pediatric Crohn's disease

Study suggests mRNA vaccines decouple SARS-CoV-2 immunity from autoantibody responses observed during acute COVID-19

Study shows how arthritis affects people's working lives

New treatment guidelines published for anorectal abscess, anal fistula, and rectovaginal fistula

Risk of severe COVID-19 in adults with immune-mediated inflammatory diseases and those on immune-modifying therapies

People with inflammatory immune conditions had increased risk of COVID-19-related death before vaccination

Trial shows the efficacy of anti-TNF drug for patients with early-stage Dupuytren's disease

Research provides a roadmap for new therapies to treat chorioamnionitis

Intensive treatment for patients with Crohn's disease found to be safe

Biosimilars could drive down drug prices and lead to $38.4 billion savings

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Hidradenitis suppurativa: Discontinuation of adalimumab prior to surgery is not necessary

Study analyzes uveitis risk after antirheumatic drug withdrawal in children with arthritis

Patient support program for painful conditions may also help avoid use of risky opioids

Shifts in care due to COVID-19 pandemic likely to drive drug expenditures in 2021

New trial to evaluate anti-TNF drug as a treatment for COVID-19 patients begins

Arrayed CRISPR Screening for Revolutionizing Target Discovery

Innovations in baculovirus–insect cell expression systems

Compound Management and its Crucial Role in Early Pharmaceutical Research

Latest News